Log in

OTCMKTS:OMBP - Omni Bio Pharmaceutical Stock Price, Forecast & News

0.00 (0.00 %)
(As of 02/16/2020 04:00 PM ET)
Today's Range
Now: $0.00
50-Day Range N/A
52-Week Range
Now: $0.00
Volume369,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.

Industry, Sector and Symbol

Industry N/A
Current SymbolOTCMKTS:OMBP



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive OMBP News and Ratings via Email

Sign-up to receive the latest news and ratings for OMBP and its competitors with MarketBeat's FREE daily newsletter.

Omni Bio Pharmaceutical (OTCMKTS:OMBP) Frequently Asked Questions

What is Omni Bio Pharmaceutical's stock symbol?

Omni Bio Pharmaceutical trades on the OTCMKTS under the ticker symbol "OMBP."

Has Omni Bio Pharmaceutical been receiving favorable news coverage?

News headlines about OMBP stock have been trending somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Omni Bio Pharmaceutical earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Omni Bio Pharmaceutical.

What other stocks do shareholders of Omni Bio Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omni Bio Pharmaceutical investors own include Xenon Pharmaceuticals (XENE), aTyr Pharma (LIFE), Flexion Therapeutics (FLXN), Biocept (BIOC), Acorda Therapeutics (ACOR) and Gemini (GKX).

Who are Omni Bio Pharmaceutical's key executives?

Omni Bio Pharmaceutical's management team includes the folowing people:
  • Dr. Leland Shapiro M.D., Principal Investigator for Viral & Bacterial Disorders

How do I buy shares of Omni Bio Pharmaceutical?

Shares of OMBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Omni Bio Pharmaceutical's stock price today?

One share of OMBP stock can currently be purchased for approximately $0.00.

MarketBeat Community Rating for Omni Bio Pharmaceutical (OTCMKTS OMBP)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Omni Bio Pharmaceutical and other stocks. Vote "Outperform" if you believe OMBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel